Gerresheimer to sell off non-core lab glass unit as part of delivery device focus

By Gareth Macdonald

- Last updated on GMT

Gerresheimer has agreed to sell its lab glassware business to a private equity investor, describing the deal as part of an effort to focus on delivery devices and pharmaceutical packaging.

Duran group – part of JPMorgan’s merchant banking arm One Equity Partners – will pay $131m (€116m) in cash for Kimble Chase Life Science and Research Products, a US-based joint venture Gerresheimer co-owns with Chase Scientific Glass.

Uwe Röhrhoff, Gerresheimer CEO, said:  “Producing laboratory glassware is not a core business for us and synergies are very limited. Together with our joint venture partner Chase Scientific Glass, Inc., we have decided to sell the business.​”

Kimble Chase has manufacturing facilities in the US, Mexico, Germany and China and employs 760 people. 

The firm generates most of its revenues - €100.7m in 2015 – in North America.

Sales for the six months to the end of June were €47.8m, down 2.6% on the comparable period last year.

News of the planned divestiture comes a yeah and a half after Gerresheimer agreed to sell its glass tubing business to Corning.

At the timeGerresheimer said the sale was part of its strategy of focusing on the development and production of “packaging solutions and delivery devices serving our pharma customers needs​."

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more